Co-Diagnostics's gross profit is $320K, below the Healthcare sector average of $64B.
Get informed when a big investor buys or sells
+ FollowAs of Mar 31, 2026
Trailing 12 months ending Mar 31, 2026
Co-Diagnostics (CODX) currently reports a gross profit of $320K as of March 2026. That compares with $2.7M in the prior-year period — down 88.1% year over year. That is below the Healthcare sector average of $64B. Use the charts on this page to explore Co-Diagnostics's gross profit history and peer comparisons.
Co-Diagnostics's gross profit decreased from $2.7M to $320K — a 88.1% year-over-year decrease (period ending March 2026). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.
Co-Diagnostics's gross profit of $320K is lower than the Healthcare sector average of $64B. That is roughly 100.0% below the sector mean. A reading lower peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.
Co-Diagnostics reported $320K in gross profit as of March 2026. That compares with $2.7M in the prior-year period — down 88.1% year over year. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.
Start with the current gross profit of $320K, then check the historical chart for trend and the peer comparison chart for relative positioning. The Healthcare average is $64B. From there, open related valuation or income-statement pages for Co-Diagnostics, and consider following CODX for alerts when major investors trade the stock.